Minocycline foam shows good efficacy for rosacea in phase 3 trials

  • Gold LS & al.
  • J Am Acad Dermatol
  • 28 Jan 2020

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • FMX103 1.5%, a minocycline 1.5% foam, is efficacious and shows good safety for patients with moderate to severe papulopustular rosacea, according to results from 2 phase 3 trials (FX2016-11 and FX2016-12).

Why this matters

  • Effective topical treatment options are lacking for patients with rosacea.

Key results

  • FMX103 1.5% was associated with a greater reduction in inflammatory lesion number compared with vehicle control:
    • −17.57 vs −15.65 (P=.0031) in the FX2016-11 trial. 
    • −18.54 vs −14.88 (P<.0001 the fx2016-12 trial.>
  • FMX103 1.5% was associated with higher rates of Investigator Global Assessment treatment success compared with vehicle control:
    • 52.1% vs 43.0% (P=.0273) in FX2016-11.
    • 49.1% vs 39.0% (P=.0077) in FX2016-12.
  • No serious treatment-related treatment-emergent adverse events (TEAEs) were reported.
  • The most common noncutaneous TEAEs were viral upper respiratory tract infection, upper respiratory tract infection, and headache.

Study design

  • FMX2016-11 included 751 patients with rosacea: 495 who received FMX103 1.5%, and 256 who received vehicle foam.
  • FMX2016-12 included 771 patients with rosacea: 514 who received FMX103 1.5%, and 257 who received vehicle foam.
  • Funding: Foamix Pharmaceuticals Inc.

Limitations

  • Selected clinical trial population may not reflect real-world scenarios.